Anakinra

Generic Name
Anakinra
Brand Names
Kineret
Drug Type
Biotech
Chemical Formula
-
CAS Number
143090-92-0
Unique Ingredient Identifier
9013DUQ28K
Background

Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the managemen...

Indication

Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combin...

Associated Conditions
Coronavirus Disease 2019 (COVID‑19), Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Idiopathic Recurrent Pericarditis, Moderately to Severely Active Rheumatoid Arthritis, Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)
Associated Therapies
-
Clinical Trials
Related News
pharmacytimes.com
·

FDA Grants Fast Track Designation to Potential Gene Therapy for Osteoarthritis of the Knee

The FDA granted fast track designation to GNSC-001, a gene therapy expressing an optimized IL-1Ra, designed for long-term inhibition of IL-1 in OA patients. Phase 1 trial data showed GNSC-001's tolerability and effectiveness in improving pain and function scores. Pharmacists' role in OA management is crucial for early detection and treatment.
biospace.com
·

Genascence Granted FDA Fast Track Designation for GNSC-001 in Patients with ...

Genascence's GNSC-001, a gene therapy for OA, received FDA Fast Track designation. GNSC-001 targets IL-1, a key mediator in OA pathogenesis, aiming for long-term inhibition with a single injection. Phase 1 data showed GNSC-001 was well-tolerated and improved pain and function scores.
dovepress.com
·

Pilot Study of IL-1 Antagonist Anakinra for Treatment of Endometriosis

A pilot study on anakinra, an IL-1 antagonist, for endometriosis-related pain shows potential benefits in reducing pain scores and inflammatory markers, with no significant impact on menstrual cycles, suggesting it could be a non-hormonal, fertility-preserving treatment option for endometriosis.

Related Clinical Trials:

Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms
news.cision.com
·

Positive Phase II study shows similar clinical outcomes of immunotherapy and antibiotic treatment for recurrent acute cystitis

A Phase II study by Hamlet BioPharma shows similar outcomes between immunotherapy and antibiotic treatment for recurrent acute cystitis, potentially reducing antibiotic use. The study, in collaboration with the University of Giessen, highlights the benefits of immunotherapy in treating this common infection, which affects many women, and could mitigate antibiotic resistance.
news-medical.net
·

Rice and Baylor receive $2.8 million to suppress inflammation and lung damage

Rice University and Baylor College of Medicine received $2.8 million from NHLBI/NIH for ARDS research. Professors Omid Veiseh and Ravi Kiran Ghanta are developing a cell therapy platform using engineered RPE cells to locally produce cytokines, aiming to reduce inflammation and lung damage in ARDS patients.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy